News

Molina Healthcare Inc (MOH) reports robust earnings and revenue growth, but faces hurdles in its Marketplace segment and regulatory pressures.

Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.

Moby summary of Molina Healthcare, Inc.'s Q2 2026 earnings call

Molina’s second quarter was complicated, with stability in Medicaid and outperformance in Medicare Advantage overshadowed by problems in the ACA exchanges. The trend was “unfortunate,” according to the insurer’s CEO.

Molina Healthcare (NYSE:MOH) shares dropped more than 9% in premarket trading on Thursday after the health insurer issued a full-year revenue outlook that disappointed investors, despite reporting second-quarter earnings ahead of market expectations. While profitability exceeded forecasts, concerns over slowing revenue growth and ongoing Medicaid headwinds weighed heavily on market sentiment.

The headline numbers for Molina (MOH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

By Padmanabhan Ananthan July 22 (Reuters) - Molina Healthcare raised its annual profit forecast on Wednesday after posting second-quarter profit and revenue that beat Wall Street estimates, helped by

Molina (MOH) delivered earnings and revenue surprises of +10.22% and -0.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The insurance company, which primarily operates through Medicare and Medicaid, said net income fell to $60 million due to lower premium revenue and an increase in the medical care ratio.

Molina healthcare has seen its stock edge down in recent days amid concerns about Medicaid cost pressures.

Healthcare insurance company Molina Healthcare (NYSE:MOH) met Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 4.8% year on year to $10.87 billion. On the other hand, the company’s full-year revenue guidance of $42 billion at the midpoint came in 5.1% below analysts’ estimates. Its non-GAAP profit of $1.51 per share was 7.8% above analysts’ consensus estimates.

CNC reports Q2 results July 28 as investors weigh improving profitability against membership declines and revenue pressure ahead of earnings.

Molina healthcare has seen its stock edge down in recent days amid concerns about Medicaid cost pressures.

Beyond analysts' top-and-bottom-line estimates for Molina (MOH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Healthcare insurance company Molina Healthcare (NYSE:MOH) will be reporting results this Wednesday after market close. Here’s what investors should know.

Molina Healthcare stock has climbed over the past year and recently touched a 52 week high after winning a large Illinois Medicaid contract, yet its valuation checks still lean expensive and the long term share price record over three years is weak. For investors, that mix of recent enthusiasm and a low value score raises the question of whether the current price already builds in much of the good news. Over the past three years, Molina Healthcare shares have declined 29.2%, which contrasts...

MOH faces lower Marketplace revenues and membership ahead of Q2 results, while Medicaid and Medicare premium growth may offset some pressure.

The core narrative surrounding UnitedHealth Group (UNH) is dominated by its successful margin recovery, yet the underlying data reveal a shift from a growth compounder to a vulnerable margin defender. The defining insight is not the massive bottom-line beat of a $6.38 adjusted earnings per share against a $4.94 consensus estimate. Rather, it is the deliberate contraction of the core membership base to support margins in the face of significant regulatory headwinds.

The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.

Elevance Health topped Q2 earnings estimates Wednesday, despite falling medical membership, but profit was boosted by one-time "below-the-line" factors and the full-year outlook was underwhelming. ELV stock tumbled, making it among the S&P 500's early laggards. Molina Healthcare, another S&P 500 managed care stock, joined Elevance among the biggest laggards performers in pre-market trading.

Investing.com -- Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, igniting a broad premarket selloff across the managed-care sector even as the insurer’s headline earnings handily beat estimates and full-year guidance was lifted.

Elevance Health is breaking the Medicare Advantage curse, and the insurer’s earnings could show it on Wednesday. Health insurer stocks have rallied this year after a tough run of rising medical costs that hampered earnings in 2024 and 2025. The results come just a day ahead of the monster of the industry, UnitedHealth Group Wall Street will be watching to see if these two companies can keep the momentum going.

UnitedHealth faces Q2 pressure from membership declines, but medical cost management and long-term growth initiatives keep investors focused on July 16 results.

Centene secures a four-year Illinois Medicaid contract renewal, preserving a key membership base and reinforcing long-term revenue stability.

CNC is turning operational improvements into margin gains, with stronger cost controls and AI-driven tools supporting profitability. Can the momentum continue?

Alignment Healthcare is using AI automation, quality plans and complex-care growth to improve Medicare Advantage economics while cost and rule pressures remain.

Alignment Healthcare's improved profits, raised 2026 outlook and stronger cash flow support the bull case, but its big rally and richer valuation raise the buy bar.

In late June 2026, Molina Healthcare, Inc. (NYSE:MOH) was removed from several Russell growth and defensive indices while being added to the Russell 2500 Index and Russell 2500 Value Benchmark. This reshuffling marks a shift in how index providers classify Molina, highlighting a tilt toward smaller-cap, value-oriented healthcare exposure after a weaker quarter. We’ll now examine how Molina’s reclassification into value-oriented indices could influence its existing investment narrative and...

Alignment Healthcare's Medicare Advantage growth, quality ratings and automation gains are lifting profitability, but 2026 execution risks remain.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.